Freedom Broker Has Lowered Expectations for Niagen Bioscience (NASDAQ:NAGE) Stock Price

Key Points

• Freedom Broker cut its price target on Niagen Bioscience to $6 from $8.50 but maintained a Buy rating; the new target implies about 190% upside from the prior close.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus Buy rating and an $8.50 average target, despite Canaccord also lowering its target, to $7 from $9.
• Shares fell 1.9% to $2.07 on Friday, near the 12-month low of $2.04. The company reported a quarterly loss of $0.01 per share, matching estimates, and revenue of $27.19 million.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) had its price target decreased by stock analysts at Freedom Broker from $8.50 to $6.00 in a report released on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Freedom Broker's price objective suggests a potential upside of 189.86% from the company's previous close.

A number of other equities analysts have also recently issued reports on the company. Roth Capital reiterated a "buy" rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Canaccord Genuity Group reduced their price target on shares of Niagen Bioscience from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Friday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $8.50.

Niagen Bioscience Trading Down 1.9%

NAGE stock traded down $0.04 during trading on Friday, reaching $2.07. 597,674 shares of the stock were exchanged, compared to its average volume of 839,384. The firm's 50 day moving average is $2.79 and its 200 day moving average is $3.85. The firm has a market cap of $164.85 million, a P/E ratio of 17.25 and a beta of 2.12. Niagen Bioscience has a twelve month low of $2.04 and a twelve month high of $7.28.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The firm had revenue of $27.19 million during the quarter. Niagen Bioscience had a return on equity of 10.26% and a net margin of 8.37%. As a group, analysts predict that Niagen Bioscience will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Niagen Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAGE. SteelPeak Wealth LLC raised its position in Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company's stock valued at $10,446,000 after buying an additional 77,306 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company's stock worth $10,489,000 after acquiring an additional 761,685 shares during the last quarter. Tieton Capital Management LLC purchased a new position in Niagen Bioscience during the 2nd quarter worth $6,407,000. Renaissance Technologies LLC boosted its holdings in Niagen Bioscience by 45.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company's stock worth $5,860,000 after acquiring an additional 414,725 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Niagen Bioscience by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company's stock worth $4,723,000 after acquiring an additional 150,763 shares in the last quarter. 15.41% of the stock is owned by institutional investors.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
• Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company's direct-to-consumer website and retail and distribution channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.